Enterprise Europe Network

Spanish biotech company offers testing services for telomere diagnostics

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
BOES20211125001
Published
03/12/2021
Last update
16/12/2021
Expiration date
17/12/2022

Keywords

Partner keyword: 
Cytology, Cancerology, Oncology
Diagnostics, Diagnosis
Environmental Medicine, Social Medicine, Sports Medicine
Medical Research
In-vitro diagnostics
Other diagnostic
Other medical/health related (not elsewhere classified)
Specialist medical practice activities
Other human health activities
EXPRESS YOUR INTEREST

Summary

Summary: 
Founded in 2010, the Spanish biotech company is a world leader in telomere diagnostics for clinical use in oncology and preventive and personalized medicine. With headquarters in Madrid, (Spain) they are an industry-leading biotechnology company working to improve people’s health and longevity. The types of partnerships considered by the company include financial agreements, joint venture agreements and commercial agency agreements.

Description

Description: 

The company offers testing services to physicians and individuals, researchers and corporations across many industries and regions, developing the adoption of telomeres and telomerase activity as key health biomarkers, advancing towards better and longer lifespans. They also use its patented technology in in vitro and clinical animal studies in the areas of nutraceuticals, biotech/pharma, infertility, veterinary and cosmetics among others for clinics, companies, researcher groups, hospitals among others.

One of its main areas of service is oncology, in which it is well advanced in offering minimally invasive blood tests for the early diagnosis of various types of cancer through the measurement of telomeres and its associated variables.

Additionally, in an impressively short of time, in March 2020, the company started to perform RT-PCR, Quick Antigens Tests, Quick Antibodies Tests, ELISA Tests and COVID Cellular Immunity Tests and has served over 400,000 clients, opening a new clinic in Madrid and becoming Spain’s mostly highly rated laboratory.

The company is now preparing to expand the business and will soon offer new tests at its clinic. These multiple tests, related to personalized and preventive medicine, will be accompanied by a medical, nutritional and/or genetic consultation.

Since 2016, the company is also Spain’s most accredited laboratory; the only U.S. Federal laboratory under Clinical Laboratory Improvement Amendments (CLIA-88) and International Organization for Standardization (ISO 15189) were completed in and all the critical aspects of the test are controlled and supervised accordingly. Moreover, its laboratories had in situ reviews annually by regulators from 2017 to 2021 with reaccreditation and satisfactory results.

The company has applied for patents and is expecting to have CE (European Conformity) marking and the International Organization for Standardization (ISO-13485) certification. In 2021, Life Length has also received the accreditation C.2.5.6 as a Diagnostic Centre with units of U.72 Obtaining Samples, U.73 Clinical Analysis and U.74 Clinical Biochemistry from the Regional Government of Madrid, Spain.

The company is expecting accreditation from the European Medicines Agency (EMA) for the use of its test in prostate cancer screening in 2022 and approval in the U.S. through the Food and Drug Administration (FDA) as an In Vitro Diagnostic (IVD), with similar pathway for lung cancer screening to commence in the near future.

The company is seeking partners in the field of diagnostic oncology for prostate and lung cancer companies from the pharma, biotech /life sciences and nutraceutical companies -for in vitro and in vivo testing and studies- as well as personalized and preventive medicine companies.

The types of partnerships considered are financial agreements, joint venture agreements and commercial agency agreements.

Advantages & innovations

Cooperation plus value: 
The Company is accredited with Clinical Laboratory Improvement Amendments (CLIA) and International Organization for Standardization (ISO) regulations, and their telomere analysis technology is focused on oncology diagnostics and prognostics. The strongest points of Telomere Analysis Technology and its quality assurance are based on the fine-tuning of the conditions required to optimize and guarantee: Accuracy; Precision Limit of Detection and Specificity. In addition, they have included a new, comprehensive data base reportable ranges and reference ranges. The company´s technology platform has the potential to become broadly applicable on a wide range of diseases, whenever the combination of disease specific Telomere-Associated Variables (TAV’s) can be combined with disease specific clinical data into a sharp cut-off algorithm for risk scoring of that disease (diagnosis or prognosis).

Technical Specification or Expertise Sought

Cooperation sought: 
The company is seeking partners in the field of diagnostic oncology for prostate and lung cancer companies from the pharma, biotech /life sciences and nutraceutical companies -for in vitro and in vivo testing and studies- as well as personalized and preventive medicine companies. The types of partnerships considered are financial agreements and joint venture agreements.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
The company is seeking companies in the fields of diagnostic oncology for prostate and lung cancer from the pharma, biotech /life sciences and nutraceutical areas, as well as personalized and preventive medicine companies to establish financial or joint venture agreements. The biotech company would be also interested in partners that wish to commercialize their services in specific geographic markets.

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,>500 MNE,SME 51-250,>500